Candesartan

Candesartan

Clinical data
Trade names	Atacand
AHFS/Drugs.com	Monograph
MedlinePlus	a601033
Pregnancy category	AU: D
Routes of administration	oral
ATC code	C09CA06 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	15% (candesartan cilexetil)
Metabolism	Candesartan cilexetil: intestinal wall; candesartan: hepatic (CYP2C9)
Biological half-life	9 hours
Excretion	Renal 33%, faecal 67%
Identifiers
IUPAC name 2-ethoxy-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid
CAS Number	139481-59-7 Y
PubChem CID	2541
IUPHAR/BPS	587
DrugBank	DB00796 Y
ChemSpider	2445 Y
UNII	S8Q36MD2XX
KEGG	D00626 N
ChEBI	CHEBI:3347 Y
ChEMBL	CHEMBL1016 Y
ECHA InfoCard	100.132.654
Chemical and physical data
Formula	C24H20N6O3
Molar mass	440.45 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(O)c1cccc2nc(OCC)n(c12)Cc5ccc(c3ccccc3c4nnnn4)cc5
InChI InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29) Y Key:HTQMVQVXFRQIKW-UHFFFAOYSA-N Y
NY (what is this?)

Candesartan (rINN) /ˌkændᵻˈsɑːrtən/ is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. The prodrug candesartan cilexetil is marketed by AstraZeneca and Takeda Pharmaceuticals, commonly under the trade names Blopress, Atacand, Amias, and Ratacand. It is available in generic form.

As with other angiotensin II receptor antagonists, candesartan is indicated for the treatment of hypertension. Results from the CHARM study (early 2000s) demonstrated the morbidity and mortality reduction benefits of candesartan therapy in congestive heart failure. Thus, while ACE inhibitors are still considered first-line therapy in heart failure, candesartan can be used in combination with an ACE to achieve improved mortality and morbidity vs. an ACE alone and additionally is an alternative in patients intolerant of ACE inhibitor therapy.

In a four-year randomized controlled trial, candesartan was compared to placebo to see whether it could prevent or postpone the development of full-blown hypertension in people with so-called prehypertension. During the first two years of the trial, half of participants were given candesartan, and the others received placebo; candesartan reduced the risk of developing hypertension by nearly two-thirds during this period. In the last two years of the study, all participants were switched to placebo. By the end of the study, candesartan had significantly reduced the risk of hypertension, by more than 15%. Serious side effects were actually more common among participants receiving placebo than in those given candesartan.